Cargando…
P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY.
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429722/ http://dx.doi.org/10.1097/01.HS9.0000969568.85601.05 |
| _version_ | 1785090782622908416 |
|---|---|
| author | Yu, Dan Cheng, Hui Guo, Jingming Jiang, Rui Zhang, Youshan Wan, Chucheng Qin, Jun Yuan, Guolin Chen, Shiming Yang, Zhuangzhi Hu, Junbin Zhang, Yicheng LI, Weiming |
| author_facet | Yu, Dan Cheng, Hui Guo, Jingming Jiang, Rui Zhang, Youshan Wan, Chucheng Qin, Jun Yuan, Guolin Chen, Shiming Yang, Zhuangzhi Hu, Junbin Zhang, Yicheng LI, Weiming |
| author_sort | Yu, Dan |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429722 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104297222023-08-17 P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY. Yu, Dan Cheng, Hui Guo, Jingming Jiang, Rui Zhang, Youshan Wan, Chucheng Qin, Jun Yuan, Guolin Chen, Shiming Yang, Zhuangzhi Hu, Junbin Zhang, Yicheng LI, Weiming Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429722/ http://dx.doi.org/10.1097/01.HS9.0000969568.85601.05 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Yu, Dan Cheng, Hui Guo, Jingming Jiang, Rui Zhang, Youshan Wan, Chucheng Qin, Jun Yuan, Guolin Chen, Shiming Yang, Zhuangzhi Hu, Junbin Zhang, Yicheng LI, Weiming P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY. |
| title | P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY. |
| title_full | P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY. |
| title_fullStr | P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY. |
| title_full_unstemmed | P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY. |
| title_short | P666: 1 YEAR RESULTS OF DASATINIB 70MG/DAY VERSUS 100MG/DAY IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE(CML-CP):A PROSPECTIVE RANDOMIZED CONTROLLED STUDY. |
| title_sort | p666: 1 year results of dasatinib 70mg/day versus 100mg/day in newly diagnosed patients with chronic myeloid leukemia in chronic phase(cml-cp):a prospective randomized controlled study. |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429722/ http://dx.doi.org/10.1097/01.HS9.0000969568.85601.05 |
| work_keys_str_mv | AT yudan p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT chenghui p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT guojingming p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT jiangrui p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT zhangyoushan p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT wanchucheng p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT qinjun p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT yuanguolin p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT chenshiming p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT yangzhuangzhi p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT hujunbin p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT zhangyicheng p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy AT liweiming p6661yearresultsofdasatinib70mgdayversus100mgdayinnewlydiagnosedpatientswithchronicmyeloidleukemiainchronicphasecmlcpaprospectiverandomizedcontrolledstudy |